Genelux Co. (NASDAQ:GNLX) Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC cut its position in Genelux Co. (NASDAQ:GNLX) by 36.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,859 shares of the company’s stock after selling 9,798 shares during the quarter. Squarepoint Ops LLC’s holdings in Genelux were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Apollon Wealth Management LLC grew its stake in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after buying an additional 2,857 shares in the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Genelux in the fourth quarter valued at $51,000. LPL Financial LLC grew its stake in shares of Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after buying an additional 39,516 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Genelux in the fourth quarter valued at $41,000. Finally, Marshall Wace LLP grew its stake in shares of Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after buying an additional 52,958 shares in the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GNLX has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Genelux in a research note on Monday, March 31st. Benchmark dropped their price objective on Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen cut Genelux from a “hold” rating to a “sell” rating in a research note on Friday, June 6th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Genelux currently has an average rating of “Moderate Buy” and a consensus price target of $17.75.

Genelux Price Performance

GNLX opened at $2.67 on Wednesday. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $5.89. The stock has a market capitalization of $100.75 million, a price-to-earnings ratio of -2.81 and a beta of -0.49. The business has a fifty day moving average price of $2.56 and a 200 day moving average price of $3.07.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, research analysts anticipate that Genelux Co. will post -0.88 earnings per share for the current year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.